Daniel Joseph Goldberg

Interests

No activities entered.

Courses

No activities entered.

Scholarly Contributions

Journals/Publications

• Abramyan, A., Schaub, D., Kalarn, S., Fitzgerald, Z., Goldberg, D., Hannallah, J., Woodhead, G., & Young, S. (2024). Including the Hollow Viscera (Stomach or Bowel) within the Ice Ball during Cryoablation: A Review of Adverse Events. Journal of vascular and interventional radiology : JVIR.
  More info

  To evaluate the safety of including hollow viscus (stomach or bowel) in the ice ball during cryoablation.
• Brunson, C., Struycken, L., Schaub, D., Ref, J., Goldberg, D., Hannallah, J., Woodhead, G., & Young, S. (2024). Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis. Abdominal radiology (New York), 49(8), 2714-2725.
  More info

  Tumorigenesis in NAFLD/NASH-induced HCC is unique and may affect the effectiveness of trans-arterial radioembolization in this population. The purpose of this study was to retrospectively compare the effectiveness of trans-arterial radioembolization for the treatment of hepatocellular carcinoma (HCC) between patients with non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) and non-NASH/NAFLD liver disease.
• Woodhead, G., Lee, S., Struycken, L., Goldberg, D., Hannallah, J., & Young, S. (2024). Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma. Life (Basel, Switzerland), 14(2).
  More info

  Surgical resection remains the cornerstone of curative treatment for intrahepatic cholangiocarcinoma (iCCA), but this option is only available to a small percentage of patients. For patients with unresectable iCCA, systemic therapy with gemcitabine and platinum-based agents represents the mainstay of treatment; however, the armamentarium has grown to include targeted molecular therapies (e.g., FGFR2 inhibitors), use of adjuvant therapy, liver transplantation in select cases, immunotherapy, and locoregional liver-directed therapies. Despite advances, iCCA remains a challenge due to the advanced stage of many patients at diagnosis. Furthermore, given the improving options for systemic therapy and the fact that the majority of iCCA patients succumb to disease progression in the liver, the role of locoregional therapies has increased. This review will focus on the expanding role of interventional radiology and liver-directed therapies in the treatment of iCCA.
• Yaari, L., Singer, J., Goldberg, D., Yassin, M., Agar, G., Lindner, D., Beer, Y., & Haviv, B. (2024). Eighteen-year outcome of anterior cruciate ligament reconstruction with patellar tendon or hamstring autograft. Archives of orthopaedic and trauma surgery, 144(5), 2189-2195.
  More info

  To evaluate patient reported outcomes and radiographic arthritic changes of transtibial anterior cruciate ligament reconstruction (ACLR) with either bone-patellar tendon-bone (BPTB) or hamstrings (HS) auto-grafts at a minimum of 15-year follow-up.
• Goldberg, D., Woodhead, G., Hannallah, J., & Young, S. (2023). Role of the Interventional Radiologist in the Treatment of Desmoid Tumors. Life (Basel, Switzerland), 13(3).
  More info

  Desmoid tumors are locally aggressive soft tissue tumors with variable clinical presentation. As is the case with most relatively rare tumors, a multidisciplinary team approach is required to best manage these patients. Surgical resection, systemic therapy, and radiation therapy have classically been mainstays of treatment for desmoid tumors; however, a more conservative "wait-and-see" approach has been adopted given their high recurrence rates and significant morbidity associated with the aforementioned therapies. Given the challenges of classical treatment methods, interventional radiologists have begun to play a significant role in minimally invasive interventions for desmoid tumors. Herein, the authors review imaging characteristics of desmoid tumors, current management recommendations, and minimally invasive therapeutic intervention options.
• Young, S., Abamyan, A., Goldberg, D., Hannallah, J., Schaub, D., Kalarn, S., Fitzgerald, Z., & Woodhead, G. (2023). Cryoablation in the liver: how accurately does the iceball predict the ablation zone?. Abdominal radiology (New York).
  More info

  To evaluate the accuracy with which the iceball predicts the realized ablation zone in patients undergoing cryoablation of the liver.
• Young, S., Hannallah, J., Goldberg, D., Khreiss, M., Shroff, R., Arshad, J., Scott, A., & Woodhead, G. (2023). Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions. Seminars in interventional radiology, 40(6), 515-523.
  More info

  In the past several decades, major advances in both systemic and locoregional therapies have been made for many cancer patients. This has led to modern cancer treatment algorithms frequently calling for active interventions by multiple subspecialists at the same time. One of the areas where this can be clearly seen is the concomitant use of locoregional and systemic therapies in patients with primary or secondary cancers of the liver. These combined algorithms have gained favor over the last decade and are largely focused on the allure of the combined ability to control systemic disease while at the same time addressing refractory/resistant clonal populations. While the general concept has gained favor and is likely to only increase in popularity with the continued establishment of viable immunotherapy treatments, for many patients questions remain. Lingering concerns over the increase in toxicity when combining treatment methods, patient selection, and sequencing remain for multiple cancer patient populations. While further work remains, some of these questions have been addressed in the literature. This article reviews the available data on three commonly treated primary and secondary cancers of the liver, namely, hepatocellular carcinoma, cholangiocarcinoma, and metastatic colorectal cancer. Furthermore, strengths and weaknesses are reviewed and future directions are discussed.
• Young, S., Hannallah, J., Goldberg, D., Sanghvi, T., Arshad, J., Scott, A., & Woodhead, G. (2023). Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape. International journal of molecular sciences, 24(14).
  More info

  Over the last several decades, a number of new treatment options for patients with hepatocellular carcinoma (HCC) have been developed. While treatment decisions for some patients remain clear cut, a large numbers of patients have multiple treatment options, and it can be hard for multidisciplinary teams to come to unanimous decisions on which treatment strategy or sequence of treatments is best. This article reviews the available data with regard to two treatment strategies, immunotherapies and locoregional therapies, with a focus on the potential of locoregional therapies to be combined with checkpoint inhibitors to improve outcomes in patients with locally advanced HCC. In this review, the available data on the immunomodulatory effects of locoregional therapies is discussed along with available clinical data on outcomes when the two strategies are combined.
• Cockburn, M., Mills, P., Zhang, X., Zadnick, J., Goldberg, D., & Ritz, B. (2011). Prostate cancer and ambient pesticide exposure in agriculturally intensive areas in California. American journal of epidemiology, 173(11), 1280-8.
  More info

  In a population-based case-control study in California's intensely agricultural Central Valley (2005-2006), the authors investigated relations between environmental pesticide/fungicide exposure and prostate cancer. Cases (n = 173) were obtained from a population-based cancer registry, and controls (n = 162) were obtained from Medicare listings and tax assessor mailings. Past ambient exposures to pesticides/fungicides were derived from residential history and independently recorded pesticide and land-use data, using a novel geographic information systems approach. In comparison with unexposed persons, increased risks of prostate cancer were observed among persons exposed to compounds which may have prostate-specific biologic effects (methyl bromide (odds ratio = 1.62, 95% confidence interval: 1.02, 2.59) and a group of organochlorines (odds ratio = 1.64, 95% confidence interval: 1.02, 2.63)) but not among those exposed to other compounds that were included as controls (simazine, maneb, and paraquat dichloride). The authors assessed the possibility of selection bias due to less-than-100% enrollment of eligible cases and controls (a critical methodological concern in studies of this kind) and determined that there was little evidence of bias affecting the estimated effect size. This study provides evidence of an association between prostate cancer and ambient pesticide exposures in and around homes in intensely agricultural areas. The associations appear specific to compounds with a plausible biologic role in prostate carcinogenesis.